follow-up note last night view label stronger
initi first glanc despit day shut increas sale number
year rais pt base increas estim launch
talk town ada late june new system offer
plethora enhanc competitor market view
re-energ salesforc drag sludgi medicar launch last
year acceler growth buyer today
view news posit read-through publicli trade partner
acceler cgm volum outweigh price pressur view
new learn call first take look last night thought
sensor could last day incorrect sensor must shut day
someth new patient adjust make sens safeti
integr close loop system price discuss assum
sensor per day compar libr closer insur coverag
pharmaci discount theori total instal base switch immedi
sensor volum would go use longer day compani
plan launch system second quarter ou later year receiv
ce mark approv medicar need get addit approv
belief improv margin profil busi
ship sensor instead sinc factori calibr compani may
may ship bgm strip meter well tbd futur iter could
includ day wear option receiv regul get comfort smart
devic like europ
though initi thought move class ii provid easier path
dxcm pipelin competit call detail limit got
sens special control rigor initi thought could actual
becom advantag depend rigor control regardless
chang creat faster way forward partner
diabeloop beta bionic biggest question think libr
hit special control bring libr market faster
hit special control lead bigfoot back partnership also
need get icgm close loop system guardian
hit special control data safeti reliabl standpoint
develop continu glucos monitor diabet manag
sale assum
net cash fulli dilut share
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
rate mention compani
overweight price target base ev/sal
assum net debt share outstand risk thesi includ govern
regulatori issu strong establish competit global insulin deliveri market
neutral price target base sale estim
assum net cash s/o risk thesi includ competit reimburs
regulatori delay
page
thousand except per share
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
